NanoCell

Company Overview

Snapshot

Founded in January 2015 by Prof. Irit Sagi, NanoCell operates with 1–10 employees. The company secured one funding round in December 2023 from Arieli Group. NanoCell is currently in the R&D product stage, focusing on a proprietary intrauterine treatment for improving embryo implantation rates.

Business overview

NanoCell is a biopharmaceutical company focused on advancing women's reproductive health. The company develops a proprietary intrauterine treatment designed to significantly improve embryo implantation rates in both humans and livestock. Its core technology involves using enzymatically remodeled extra-cellular matrix (ECM) to enhance the efficiency of embryo implantation. NanoCell operates within the Health Tech & Life Sciences sector, specifically targeting the medical devices, pharma & medical biotechnology, and medical treatment & therapeutics markets.

Company Intelligence Q&A

What is NanoCell's primary focus?

NanoCell is dedicated to advancing women's reproductive health through biopharmaceutical technologies, specifically focusing on improving embryo implantation rates.

Who founded NanoCell?

NanoCell was founded by Prof. Irit Sagi in January 2015.

What is NanoCell's core technology?

NanoCell is developing a method, kit, and composition for increasing the implantation rate of embryos using enzymatically remodeled extra-cellular matrix (ECM).

What is the current status of NanoCell?

NanoCell is currently non-active, having ceased operations in August 2024.

In which sector does NanoCell primarily operate?

NanoCell operates in the Health Tech & Life Sciences sector, with a focus on medical devices and biopharmaceutical solutions.